Ontology highlight
ABSTRACT: Background
Chronic total occlusion (CTO) remains the most complex anatomical subset of lesions in percutaneous coronary intervention (PCI), often requiring advanced techniques and technologies, including the use of microcatheters.Methods
The BIOMICS study is a premarket first-in-human prospective, multicenter, open-label, single-arm trial investigating the safety and efficacy of a novel coronary microcatheter (BioMC, Biosensors International) in 100 patients with symptoms of ischemia undergoing elective CTO-PCI. The primary efficacy end point of the study was device success defined according to the CTO-ARC (Chronic Total Occlusion Academic Research Consortium) criteria namely the ability of the microcatheter to successfully facilitate placement of a guide wire beyond the occluded coronary segment. The primary safety end point was the incidence of in-hospital cardiac death or myocardial infarction at hospital discharge.Results
Hundred patients were recruited between March 2022 and January 2023. The primary efficacy end point was achieved in 75% of patients (95% CI, 65.3%-83.1%; P < .0001 for superiority compared to the prespecified performance goal of 54%). The primary safety end point of in-hospital cardiac death or myocardial infarction was observed in 2% of the patients. There were no study device-related coronary perforations or device failures.Conclusions
The use of a novel coronary microcatheter during CTO-PCI was associated with a high device success and an excellent safety profile.
SUBMITTER: Sidik N
PROVIDER: S-EPMC11308310 | biostudies-literature | 2024 Jul
REPOSITORIES: biostudies-literature
Sidik Novalia N McEntegart Margaret M Joshi Francis F Owens Colum C Shaukat Aadil A Gallagher Sean S Strange Julian J Tang Kare K Elghamaz Ahmed A Mozid Abdul A Ladwiniec Andrew A Oldroyd Keith K Schuette Diana D Copt Samuel S Spratt James C JC
Journal of the Society for Cardiovascular Angiography & Interventions 20240518 7
<h4>Background</h4>Chronic total occlusion (CTO) remains the most complex anatomical subset of lesions in percutaneous coronary intervention (PCI), often requiring advanced techniques and technologies, including the use of microcatheters.<h4>Methods</h4>The BIOMICS study is a premarket first-in-human prospective, multicenter, open-label, single-arm trial investigating the safety and efficacy of a novel coronary microcatheter (BioMC, Biosensors International) in 100 patients with symptoms of isch ...[more]